证券代码：600257 证券简称：大湖股份 公告编号：2023-020 大湖水殖股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 关于召开 2022 年度业绩说明会的公告 重要内容提示： 会议召开时间：2023 年 06 月 09 日(星期五)下午 15:00-16:30 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址:http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络视频和网络文字互动 投资者可于 2023 年 06 月 02 日(星期五)至 06 月 08 日(星期 四)16:00 前登录上证路演中心网站首页点击"提问预征集"栏 目或通过公司邮箱 925286482@qq.com 进行提问。公司将在说明 会上对投资者普遍关注的问题进行回答。 大湖水殖股份有限公司（以下简称"公司"）已于 2023 年 4 月 26 日披露公司 2022 年年度报告，为便于广大投资者更全面深入地了 解公司 2022 年度经营成果、财务状况，公 ...

Financial Performance - The company's operating revenue for 2022 was CNY 1,094,712,820.42, a decrease of 15.29% compared to CNY 1,292,312,436.98 in 2021[23] - The net profit attributable to shareholders of the listed company was a loss of CNY 71,495,117.40, an improvement of 60.31% from a loss of CNY 180,118,858.50 in the previous year[23] - The net cash flow from operating activities was CNY 97,866,143.08, showing a slight increase of 1.50% compared to CNY 96,420,908.67 in 2021[23] - Total assets at the end of 2022 were CNY 2,161,876,319.04, down 7.63% from CNY 2,340,424,356.56 at the end of 2021[23] - The net assets attributable to shareholders of the listed company decreased by 7.34% to CNY 879,723,654.23 from CNY 949,434,742.91 in 2021[23] - Basic earnings per share improved by 59.46% from -0.37 CNY in 2021 to -0.15 CNY in 2022[24] - Diluted earnings per share also increased by 59.46% from -0.37 CNY in 2021 to -0.15 CNY in 2022[24] - The weighted average return on equity improved by 9.38 percentage points from -17.2% in 2021 to -7.82% in 2022[24] - The company reported a net loss of CNY 219,125,049.68 for the year, compared to a loss of CNY 147,629,932.28 in the previous year, indicating a worsening of approximately 48.4%[192] - The company reported a total revenue of $1.06 billion from offline sales, down 15.80% year-over-year, with a gross margin of 23.19%, decreasing by 3.94 percentage points[64] Revenue Breakdown - The company faced a decrease in revenue from its main business, with a reported figure of CNY 1,085,246,159.37, down 15.51% from CNY 1,284,524,215.94 in the previous year[23] - Total revenue for Q1 2022 was 219,017,105.58 CNY, while Q2 was 320,603,898.69 CNY, Q3 was 288,475,793.47 CNY, and Q4 was 266,616,022.68 CNY[26] - The total revenue from the medical services segment was $222.95 million, with a gross margin of 28.26%, reflecting a year-over-year increase of 3.66%[64] - The total revenue from online sales was $23.38 million, with a gross margin of 39.71%, showing a slight decrease of 0.32% year-over-year[64] - The company’s total revenue from the central-south region was $732.74 million, down 21.99% year-over-year, with a gross margin of 23.55%, a decrease of 1.26 percentage points[64] - The total revenue from the east China region was $279.79 million, reflecting a year-over-year increase of 14.18%, with a gross margin of 25.68%, down 13.94 percentage points[64] Cost Management - The company reported a 10.84% reduction in operating costs, totaling CNY 835,395,069.46[61] - The company reported a significant decrease in selling expenses, which fell to CNY 59,120,971.80 in 2022 from CNY 95,535,225.90 in 2021, a reduction of approximately 38%[200] - Total operating costs for 2022 were CNY 1,100,011,040.37, down from CNY 1,244,399,571.64 in 2021, reflecting a reduction of about 11.6%[199] Investments and R&D - Research and development expenses increased by 160.99%, reaching CNY 947,656.36[61] - Research and development expenses increased to CNY 947,656.36 in 2022 from CNY 363,103.11 in 2021, representing a growth of approximately 161.5%[200] Governance and Compliance - The company maintained a robust governance structure, adhering to relevant laws and regulations to protect shareholder rights[88] - The board of directors convened 9 meetings, ensuring compliance with governance standards and effective oversight[89] - The company held 1 annual and 2 temporary shareholder meetings during the reporting period, with all resolutions passed without any objections[90] Market and Strategic Initiatives - The company focused on optimizing product structure and enhancing sales channels to support its health product and health service strategy[33] - The aquaculture division emphasized ecological breeding and sustainable practices to produce high-quality organic freshwater products[33] - The company aims to upgrade and transform into a comprehensive health industry by integrating health products and services[33] - The company has established a pre-prepared dish industrial park with a total area of 46,700 square meters, including a cold storage area of over 1,900 square meters, expected to increase production capacity by 15,700 tons[34] Employee and Management - The total number of employees in the parent company is 211, while the main subsidiaries employ 1,480, resulting in a total of 1,691 employees[112] - The total remuneration for all directors, supervisors, and senior management was 4.286 million yuan[102] - The company emphasizes the importance of grassroots employee compensation, directing performance rewards primarily to frontline staff[114] Environmental and Social Responsibility - The company invested 263.49 million yuan in environmental protection during the reporting period[122] - The company has contributed a total of 32.65 million yuan to poverty alleviation and rural revitalization projects, including 20 million yuan to support a specific village[127] - The company is committed to ecological sustainability in its operations, aligning with government initiatives for high-quality green development[169] Acquisitions and Partnerships - The company acquired 60% equity in Dongfang Huakang for a total cash consideration of 250 million RMB, including 50 million RMB for 8% equity and 200 million RMB for 32% equity, along with a capital increase of 12.5 million RMB[133] - The company and its subsidiary invested RMB 27 million each to hold 90% equity in two newly established hospitals, Shanghai Jinxian Rehabilitation Hospital and Shanghai Fengxiang Nursing Home[150] Future Outlook - The company has plans for market expansion and new product development in the upcoming fiscal year[168] - The overall financial performance indicates a stable growth trajectory, with a focus on enhancing user engagement and product offerings[168]

2023 年第一季度报告 证券代码：600257 证券简称：大湖股份 大湖水殖股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同期增减 变动幅度(%) | | | --- | --- | --- | --- | | 营业收入 | 250,086,468.74 | | 14.19 | | 归属于上市公司股东的净利润 | -9,137,404.94 | | 30.75 | | 归属于上市公司股东的扣除非经常 | -11,199,650.32 | | 25.43 | | 性 ...

2022 年第三季度报告 证券代码：600257 证券简称：大湖股份 大湖水殖股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比 上年同期增减变动 | | --- | --- | --- | --- | --- | | | | 增减变动幅度(%) | | | | | | | | 幅度(%) | | 营业收入 | 288,475,793.47 | -17.39 | 828,096,797.74 | -11.52 | | 归属 ...

证券代码：600257 证券简称：大湖股份 公告编号：2022-048 大湖水殖股份有限公司 关于参加 2022 年湖南辖区上市公司 投资者网上集体接待日活动的公告 本公司及董事会全体成员保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担个别及连带责任。 为进一步加强与投资者的互动交流，使广大投资者能更深入 全面地了解大湖水殖股份有限公司（以下简称"公司"）情况，公 司将参加由中国证券监督管理委员会湖南监管局、湖南省上市公 司协会和深圳市全景网络有限公司联合举办的"湖南辖区上市公 司投资者网上接待日活动"，现将有关事项公告如下： 本次投资者网上接待日活动将通过深圳市全景网络有限公 司提供的互联网平台举行，投资者可以登录"全景·路演天下" 网站（http://rs.p5w.net），参与公司本次投资者网上接待日活 动，活动时间为 2022 年 9 月 29 日（星期四）下午 14:00 至 17:00， 下午 15:30 开始上市公司与投资者网上互动环节。 届时公司董事会秘书及证券事务代表将通过网络文字交流 形式与投资者进行沟通与交流。欢迎广大投资者积极参与。 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥539,621,004.27, a decrease of 8.02% compared to ¥586,683,773.82 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was a loss of ¥14,233,928.27, a decline of 282.73% from a profit of ¥7,789,781.05 in the previous year[18]. - The net cash flow from operating activities was a negative ¥103,974,462.55, worsening from a negative ¥27,929,507.43 in the same period last year, representing a decline of 272.27%[18]. - Basic earnings per share for the first half of 2022 were -¥0.0301, a decrease of 285.8% compared to ¥0.0162 in the same period last year[19]. - The weighted average return on net assets was -1.54%, a significant decline from 0.67% in the previous year[19]. - The total revenue for the first half of 2022 was approximately ¥56,544,557.23, showing a significant increase compared to the previous period[84]. - The net profit for the first half of 2022 was a loss of ¥12,408,701.60, compared to a profit of ¥17,357,586.26 in the same period of 2021[116]. - The total operating revenue for the first half of 2022 was ¥539,621,004.27, a decrease of 8.01% compared to ¥586,683,773.82 in the same period of 2021[115]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,255,354,603.97, down 3.63% from ¥2,340,424,356.56 at the end of the previous year[18]. - The net assets attributable to shareholders of the listed company decreased by 1.50% to ¥935,200,814.65 from ¥949,434,742.91 at the end of the previous year[18]. - The company's total assets as of June 30, 2022, amounted to ¥1,683,889,870.37, an increase from ¥1,671,235,752.66 at the end of 2021[113]. - Total liabilities as of June 30, 2022, were ¥654,938,308.96, slightly up from ¥653,485,204.21 at the end of 2021[113]. - The total liabilities decreased from CNY 1,265,140,435.82 to CNY 1,194,085,000.82, a decline of about 5.59%[107]. Cash Flow and Investments - The company's cash and cash equivalents decreased by 60.21%, from CNY 340,891,113.94 to CNY 135,648,767.86, primarily due to significant investments in two new rehabilitation hospitals in Hangzhou[49]. - The company reported a net cash outflow from investing activities of CNY 36,720,694.99, an improvement of 63.91% compared to the previous year's outflow of CNY 101,743,149.03[49]. - The company received RMB 150 million in borrowings during the first half of 2022, compared to RMB 390.5 million in the same period of 2021, indicating a decrease in financing activities[124]. - The net cash flow from investing activities was -¥15,176,732.76, compared to -¥151,321,948.85 in the previous period, indicating a significant reduction in cash outflow[129]. Business Segments and Operations - The main business segments include health product production and sales, as well as health medical service management, focusing on the synergy between these two areas[23]. - The company operates multiple rehabilitation and nursing institutions, targeting elderly, children, and patients, with a comprehensive service offering in rehabilitation care[26]. - The revenue from the aquaculture segment accounted for 57% of total revenue in the first half of 2022[43]. - The health medical service segment's revenue accounted for 19% of total revenue in the first half of 2022[45]. - The company is committed to upgrading its business model towards a comprehensive health industry, focusing on health products and services[45]. Market Trends and Demand - The demand for ready-to-eat seafood products is rapidly increasing, with the market expected to exceed RMB 800 billion by 2025, and the sauerkraut fish segment projected to reach RMB 1.69 billion[31]. - The rehabilitation medical market in China is expected to surpass RMB 220 billion by 2025, driven by an aging population and increasing rehabilitation needs[35]. - The total area of aquaculture in China has shown a declining trend, with a 1.12% decrease in freshwater aquaculture area in 2022, yet the overall production of aquatic products remains stable[28]. Research and Development - The company has made significant advancements in research and innovation, including the development of key technologies for freshwater fish deep processing, which have received provincial and national awards[38]. - Research and development expenses dropped significantly by 93.13%, from CNY 2,855,049.36 to CNY 196,052.02[49]. - The company is focused on ecological breeding models and has made progress in breeding disease-resistant fish varieties, ensuring high-quality fish production[38]. Corporate Governance and Shareholding - The total number of ordinary shareholders as of the end of the reporting period was 65,349[94]. - The largest shareholder, Tibet Hongshan Technology Development Co., Ltd., holds 104,631,211 shares, accounting for 21.74% of the total shares[96]. - The company has not reported any stock buyback accounts among the top ten shareholders[97]. Strategic Initiatives - The company has initiated the operation of two new rehabilitation hospitals in Hangzhou as part of its market expansion strategy[50]. - The company plans to invest CNY 276 million in a prepared food processing project, with CNY 220 million allocated for the construction of a processing center and base, expected to increase production capacity by 15,700 tons[42]. - The company is enhancing its marketing channels by integrating online and offline sales, including direct sales, agency, group buying, and e-commerce platforms[44]. Sustainability and Ecological Practices - The company emphasizes ecological and sustainable development in aquaculture, aligning with national policies promoting green practices in the industry[27]. - The company has adopted an ecological breeding model for fish farming, focusing on low energy consumption and pollution, aligning with national green development initiatives[62]. - The company is focusing on ecological aquaculture and has adopted strategies for sustainable development, including the use of lake biological governance and nutrient control technologies[41].

Financial Performance - The company's operating revenue for 2021 was approximately CNY 1.29 billion, representing a 37.99% increase compared to CNY 936.52 million in 2020[21]. - The net profit attributable to shareholders for 2021 was a loss of approximately CNY 180.12 million, a decrease of 4,417.79% compared to a profit of CNY 4.17 million in 2020[22]. - The net cash flow from operating activities for 2021 was approximately CNY 96.42 million, a significant improvement of 387.10% compared to a negative cash flow of CNY 33.58 million in 2020[22]. - Total assets at the end of 2021 were approximately CNY 2.34 billion, an increase of 18.89% from CNY 1.97 billion at the end of 2020[22]. - The company's net assets attributable to shareholders decreased by 18.4% to approximately CNY 949.43 million at the end of 2021, down from CNY 1.16 billion at the end of 2020[22]. - The basic earnings per share for 2021 was -0.37 RMB, a decrease of 4,352.87 percentage points compared to 2020[23]. - The weighted average return on net assets was -17.20%, down 17.56 percentage points from the previous year[23]. - The company reported a significant loss in the fourth quarter, with a net profit attributable to shareholders of -200.37 million RMB[27]. - The company reported a net profit of ¥3,864,000 from Oriental Huakang Medical Management Co., Ltd. for the reporting period[77]. - The company reported a total loss of -180,118,858.50, which reflects a decline in financial performance[198]. Revenue Segmentation - The revenue from the aquaculture segment accounted for 58.65% of the total, representing a year-on-year growth of 24.36%, with frozen aquatic products sales increasing by 280.16%[35]. - The health liquor segment's revenue share was 10.86%, showing a significant year-on-year increase of 49.95%[36]. - The health medical services segment's revenue share reached 16.74%, with a remarkable year-on-year growth of 530.07%[38]. Business Strategy and Development - The company plans to upgrade its business model towards a comprehensive health industry, integrating health products and services[33]. - The company is focusing on the development of a "medical, nursing, and rehabilitation" integrated model in its health services[38]. - The company is investing in the establishment of rehabilitation hospitals and nursing homes to enhance its presence in the health service industry[38]. - The company is adapting to changing consumer preferences by increasing the sales proportion of frozen and ready-to-eat products[35]. - The company is implementing a brand marketing strategy focused on key regions such as the Greater Bay Area and Yangtze River Delta[35]. - The company is enhancing its management capabilities and optimizing resource allocation to support business development[38]. Risk Management - The company reported no significant risks that could materially affect its operations during the reporting period[9]. - The company has not engaged in non-operating fund occupation by controlling shareholders or related parties[7]. - The company has not violated decision-making procedures for external guarantees[7]. - The company emphasizes the importance of investor awareness regarding potential risks in its future plans and strategies[6]. - The company faces competition risks from pond-cultured fish, which have higher yields compared to the company's naturally farmed fish[79]. - The company faces risks from food safety issues that could impact reputation and sales, and plans to enhance quality control and internal management systems[80]. - Rising operational costs, including labor and breeding expenses, pose a risk, and the company intends to mitigate this through refined management and brand enhancement strategies[80]. Corporate Governance - The company held 1 annual and 2 temporary shareholder meetings during the reporting period, with a total of 16 resolutions passed, including 1 special resolution[88]. - The total remuneration for the board members and senior management during the reporting period amounted to CNY 4.5176 million[90]. - The company has maintained a stable management team with no changes in shareholding among directors and supervisors[90]. - The company has a structured compensation decision-making process involving the board's remuneration committee and shareholder meetings[98]. - The company has a total of 6 specialized committees under the board, including the Audit Committee and the Strategic Committee[104]. Social Responsibility and Sustainability - The company actively engages in social responsibility, focusing on protecting the rights of shareholders, employees, and the environment[119]. - The company has donated a total of 268,200 CNY to support rural revitalization projects, with specific contributions of 150,000 CNY to the Yanglouping Village project and 100,000 CNY to the Dongliuxi Village project[123]. - The company has released over 100 million high-quality fish fry to protect the aquatic ecological environment over the past decade[121]. - The company adheres to an ecological farming model, promoting sustainable aquaculture practices that align with national green development initiatives[118]. Investment and Financial Management - The company has invested ¥20,000,000 in bank fixed-term wealth management products, with no overdue amounts[154]. - The company has allocated ¥30,000,000 to structured deposits, also with no overdue amounts[154]. - The company has invested ¥22,999,000 in corporate/retirement wealth management products, with a remaining balance of ¥20,000,000[154]. - The company has pledged its 60% equity stake in Oriental Huakang Medical Management Co., Ltd. as collateral for a bank loan of ¥368,078,828.90, with a loan term of 84 months at an interest rate of 4.65%[72]. Employee Management - The total number of employees in the parent company is 342, while the main subsidiaries employ 1,477, resulting in a total of 1,819 employees[107]. - The company emphasizes performance management and has implemented a performance evaluation system for subsidiaries, focusing on aligning employee compensation with company performance[108]. - The company maintains a moderate increase in employee wages, ensuring that the growth rate of employee income does not exceed the company's performance growth rate[109].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 219,017,105.58, representing a decrease of 18.21% compared to the same period last year[6]. - The net profit attributable to shareholders of the listed company was a loss of CNY 13,194,146.45, with a diluted earnings per share of -0.0274 yuan[7]. - The net cash flow from operating activities was -CNY 57,552,807.28, a significant decline of 90.97% year-on-year[6]. - Total operating revenue for Q1 2022 was ¥219,017,105.58, a decrease of 18.2% compared to ¥267,767,402.54 in Q1 2021[23]. - Net profit for Q1 2022 was a loss of ¥13,072,794.39, compared to a profit of ¥9,710,054.34 in Q1 2021, representing a significant decline[24]. - The company reported a net loss of RMB 160,824,078.73 for the period, compared to a loss of RMB 147,629,932.28 in the previous period, indicating a worsening of approximately 8.5%[20]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,258,071,834.82, down 3.52% from the end of the previous year[7]. - The company's current assets totaled RMB 1,006,157,717.97, down from RMB 1,091,283,500.44, indicating a decrease of about 7.8%[18]. - Cash and cash equivalents were reported at RMB 215,896,512.45, significantly lower than RMB 340,891,113.94 from the previous year, representing a decline of approximately 36.7%[18]. - The company's total liabilities decreased to RMB 1,197,466,324.47 from RMB 1,265,140,435.82, marking a reduction of about 5.3%[20]. - Total assets decreased from CNY 1,671,235,752.66 to CNY 1,618,102,028.53, a decline of approximately 3.2%[32]. - Total liabilities decreased from CNY 653,485,204.21 to CNY 611,689,352.32, a reduction of approximately 6.4%[32]. Cash Flow - The company reported a net cash outflow from operating activities of ¥57,552,807.28 in Q1 2022, compared to an outflow of ¥30,137,168.38 in Q1 2021[27]. - In Q1 2022, the company's net cash flow from operating activities was ¥10,710,332.40, a significant improvement from a net outflow of ¥37,919,803.99 in Q1 2021[38]. - The company reported a net cash flow from investing activities of -¥14,977,147.98, an improvement from -¥154,744,533.02 in Q1 2021[39]. - The net cash flow from financing activities was -¥33,723,973.89, compared to a positive net flow of ¥177,735,737.48 in Q1 2021[39]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 84,451[13]. - The largest shareholder, Tibet Hongshan Technology Development Co., Ltd., held 21.74% of the shares, with 51,340,000 shares pledged[14]. Expenses and Investments - The company incurred a significant increase in tax expenses, totaling ¥4,937,603.91 in Q1 2022, compared to ¥644,178.31 in Q1 2021[24]. - Research and development expenses decreased to ¥57,003.97 in Q1 2022 from ¥265,346.06 in Q1 2021, indicating a reduction in investment in innovation[23]. - The company reported a loss from investment activities of ¥361,084.60 in Q1 2022, contrasting with a gain of ¥386,943.97 in Q1 2021[23]. - Total cash inflow from investment activities was ¥62,070,592.22 in Q1 2022, compared to ¥610,048.23 in Q1 2021, reflecting a decrease in investment returns[28].

Financial Performance - The company's operating revenue for Q3 2021 was ¥349,189,567.18, representing a year-on-year increase of 40.19%[4] - The net profit attributable to shareholders for the same period was ¥12,461,543.69, a significant increase of 730.10% compared to the previous year[4] - The net profit after deducting non-recurring gains and losses reached ¥8,775,699.22, up by 783.50% year-on-year[4] - Total operating revenue for the first three quarters of 2021 reached ¥935,873,341, a significant increase from ¥641,653,192.82 in the same period of 2020, representing a growth of approximately 46%[19] - Net profit for the first three quarters of 2021 was ¥33,451,468.01, up from ¥5,047,917.33 in 2020, marking a substantial increase of approximately 563%[20] - The net profit attributable to shareholders of the parent company was ¥20,251,324.74, compared to ¥5,679,446.57 in the previous year, reflecting an increase of around 256%[20] - The company reported a total comprehensive income of ¥33,286,877.80 for the first three quarters of 2021, compared to ¥4,919,664.44 in the same period of 2020, indicating a growth of around 576%[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,338,319,355.04, reflecting an 18.79% increase from the end of the previous year[5] - The company's total liabilities amounted to ¥1,031,124,881.10, an increase from ¥669,327,720.34 in the previous year, showing a growth of approximately 54%[19] - The company’s total liabilities are reported at ¥625,743,371.70, slightly down from ¥633,929,740.98[14] - The total assets as of the end of 2021 amounted to CNY 1,968,514,403.28, a decrease from CNY 2,161,733,754.55 at the end of 2020[28] - Total current liabilities amounted to 633,929,740.98, a decrease of 23,648,673.98 from the previous period[29] - Total non-current liabilities increased to 35,397,979.36, reflecting a significant rise of 194,849,764.09 compared to the previous period[29] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥48,659,359.41, showing a 154.17% increase[4] - Operating cash flow for the first three quarters of 2021 was CNY 48,659,359.41, a significant improvement from a negative cash flow of CNY -89,822,815.63 in the same period of 2020[24] - Total cash inflow from investment activities increased to CNY 89,332,364.12 in 2021, compared to CNY 11,273,173.76 in 2020[25] - Cash outflow for investment activities rose to CNY 219,121,946.20 in 2021, up from CNY 99,860,311.36 in 2020, resulting in a net cash flow from investment activities of CNY -129,789,582.08[25] - Cash inflow from financing activities reached CNY 424,963,786.50 in 2021, compared to CNY 251,950,000.00 in 2020, while cash outflow for financing activities was CNY 293,975,553.53, up from CNY 181,120,868.01[25] Shareholder Information - The total number of common shareholders at the end of the reporting period is 61,946[9] - The largest shareholder, Tibet Hongshan Technology Development Co., Ltd., holds 104,631,211 shares, accounting for 21.74% of total shares[9] - The company has a total of 51,340,000 shares pledged by the largest shareholder[9] Expenses - The financial expenses surged by 296.04% due to the implementation of new leasing standards and increased bank loans[7] - The company incurred financial expenses of ¥26,052,565.97, which is a significant increase from ¥6,578,347.21 in the previous year, reflecting an increase of approximately 296%[19] - Research and development expenses for the first three quarters of 2021 were ¥3,116,109.96, slightly down from ¥3,355,561.06 in 2020, showing a decrease of about 7%[19] Inventory and Receivables - The company’s inventory stands at ¥524,535,923.33, a decrease from ¥565,611,169.00[13] - The company’s accounts receivable increased to ¥248,171,335.80 from ¥203,588,481.76[13] Future Plans - The company plans to expand its market presence and enhance product offerings, although specific new products or technologies were not detailed in the report[4]

证券代码：600257 证券简称：大湖股份 公告编号：2021-028 大湖水殖股份有限公司 关于参加 2021 年湖南辖区上市公司 投资者网上接待日活动的公告 本公司及董事会全体成员保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担个别及连带责任。 为进一步加强与投资者的互动交流，使广大投资者能更深入 全面地了解大湖水殖股份有限公司（以下简称"公司"）情况，公 司将参加由中国证券监督管理委员会湖南监管局、湖南省上市公 司协会和深圳市全景网络有限公司联合举办的"湖南辖区上市公 司投资者网上集体接待日活动"，现将有关事项公告如下： 本次投资者网上接待日活动将通过深圳市全景网络有限公 司提供的互联网平台举行，投资者可以登录"全景·路演天下" 网站（http://rs.p5w.net），参与公司本次投资者网上接待日活 动，活动时间为 2021 年 9 月 24 日（星期五）下午 15:00 至 17:00。 届时公司董事会秘书等相关人员将通过网络文字交流形式 与投资者进行沟通与交流。欢迎广大投资者积极参与。 特此公告。 大湖水殖股份有限公司董事会 2021 年 9 ...